Thyroid Cancers | Clinical

November 11, 2021

Yuliya Mikheeva, MD, PhD, of Saint Petersburg State University, discusses the prognosis of patients with anaplastic thyroid cancer.

October 29, 2021

Extended follow-up of patients in COSMIC-311 showed continued survival benefit and tumor reduction with cabozantinib versus placebo in patients with radioactive iodine-refractory differentiated thyroid cancer.

October 22, 2021

The ATLEP study explored the combination of lenvatinib and pembrolizumab in patients with ATC and poorly differentiated thyroid cancer.

October 14, 2021

Theodore W. Laetsch, MD, an attending physician at the Cancer Center at Children’s Hospital of Philadelphia, discusses the safety profile of larotrectinib in thyroid cancer and other solid tumors.

October 13, 2021

In an interview with Targeted Oncology, Marcia S. Brose, MD, PhD, discussed a multiple trial analysis of patients treated with larotrectinib over a median of 24 months.

October 12, 2021

The panel of experts share their treatment recommendations for a 64-year-old woman with RET wild-type metastatic MTC.

October 12, 2021

Dr Marcia Brose reviews key efficacy and safety data from the phase 3 ZETA and EXAM clinical trials.

October 12, 2021

Marcia Brose, MD, presents the case of a 64-year-old woman with RET wild-type metastatic medullary thyroid cancer.

October 07, 2021

The 140 mg dosage was associated with a higher rate of adverse events and dose reductions.

October 07, 2021

A subgroup analysis of the phase 3 COSMIC-311 study revealed no key differences in the survival and responses observed with cabozantinib based on the age of patients with RAI-refractory differentiated thyroid cancer.